07-23 2025

Novatim and Erigen Enter Exclusive Licensing Agreement for Dual-Target CAR-T Therapy KQ-2003 excluding Greater China/India/Turkey and Russia

Novatim's dual-target CAR-T therapy KQ-2003 has been out-licensed for territories outside Greater China

02-12 2025

BCMA/CD19 dual-target CAR-T cell therapy shows significant efficacy in the treatment of POEMS syndrome

02-22 2024

聚势创变，赋能共赢 | 科弈药业与思路迪医药签署战略合作协议

科弈药业与思路迪医药战略合作签约！

01-18 2024

科弈药业KQ-2003双靶点CAR-T细胞临床研究者会议在浙江安吉隆重召开

科弈药业KQ-2003双靶点CAR-T细胞临床研究者会议在浙江安吉隆重召开

10-23 2023

科弈药业创新药入选2023年“南太湖精英计划”

科弈（浙江）药业科技有限公司申报的“用于治疗晚期恶性肿瘤的靶向PD-1的新型IL-2融合蛋白的研发和产业化”成功入选浙江省湖州市2023年第一批“南太湖精英计划”创新创业人才项目。